



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Date: 30th June, 2021

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Security Code: 524400

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 30th June, 2021

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its Board Meeting held on 30th June, 2021, Inter alia:

1. Considered and approved Audited Financial Results of the Company for the quarter and year ended on 31st March, 2021.
2. Considered and approved the re-appointment of M/s Meenu Maheshwari & Associates, Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2021-22.
3. Considered and approved the re-appointment of Internal Auditors of the Company for the year 2021-22.
4. Considered and approved the Director's Report with the Annexure, Corporate Governance Report, Management Discussion and Analysis Report and Notice for convening the 28th Annual General Meeting of the Company.
5. Taken on record the Disclosure of Interest of Directors of the Company for the year 2021-22.

A declaration under SEBI Circular CIR/CFD/CMD/56/2016 Dated 26th May, 2016, in respect of Statutory Auditor's issued Audit Report with unmodified opinion for financial results for the financial year ended March 31, 2021 enclosed herewith.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited


Srushti Pandya

Company Secretary and Compliance Officer



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Auditors Report on Annual Financial Results of M/s Ishita Drugs & Industries Ltd. Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
Board Of Directors,
Ishita Drugs & Industries Ltd

We have audited the statement of annual financial result of M/s **Ishita drugs & industries Ltd** for the year ended 31 march, 2021. Attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (listing obligation and Disclosure requirements) Regulations, 2015. These statement is the responsibility of the company's management and has been approved by the boards of directors. This statement has been prepared on the basis of the Generally Accepted Accounting Principles and policies. Our responsibility is to express an opinion on these financial results based on our audit of such annual financial statement. Which have been prepared in accordance with the recognition and measurement principles laid down in accounting standard for interim financial reporting (Ind-AS 34), prescribed, under section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial result are free of material misstatement(S). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best information and according to the explanations given to us these financial result.

- (i) Are presented in accordance with the requirements of regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 in this regards and
- (ii) Give a true and fair view of the net profit and other financial information for the period from 01 April, 2020 to 31 March,2021.





Office Address :

C-10 Soham Complex,
2nd Floor, Soni ni Chawl, Cross Road,
Odhav, Ahmedabad-382415

The financial result include the result for the quarter ended March 31, 2021 being the balancing figure between audited figure in respect of full financial year and the published year to date figures upto the third quarter of the financial year, which were subject to limited review by us.

Date: 30/06/2021

Place: Ahmedabad

**For and on Behalf of
JAYMIN SHAH AND ASSOCIATES**

Mayank Sancheti
Mayank Sancheti
(Partner)
M.No.: 170863
FRN: 129406W
UDIN: 21170863AAAACZ1230

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Audited Financial Results for the Quarter and Year Ended March 31, 2021



Amount in Lakhs except Per Share data

| Particulars | 3 Months Ended | Preceding 3 Months Ended | Corresponding 3 Months Ended in the previous Year | Year to date figures for current year ended | Year to date figures for previous year ended |
|---|----------------|--------------------------|---|---|--|
| | 31-Mar-21 | 31-Dec-20 | 31-Mar-20 | 31-Mar-21 | 31-Mar-20 |
| | Audited | Un-audited | Audited | Audited | Audited |
| 1 INCOME | | | | | |
| Revenue from Operations | 401.89 | 382.98 | 336.51 | 1394.90 | 1483.23 |
| Other Income | 26.27 | 1.03 | 5.39 | 31.36 | 16.23 |
| Total Income | 428.16 | 384.01 | 341.90 | 1426.26 | 1499.46 |
| 2 EXPENSES | | | | | |
| (a) Cost of Material Consumed | 226.27 | 272.52 | 219.17 | 956.40 | 1135.53 |
| (b) Purchase of Stock-In-Trade | 49.05 | 12.66 | 6.35 | 63.18 | 9.25 |
| (c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade | 6.96 | 14.05 | 7.74 | 9.13 | (0.27) |
| (d) Employee Benefit Expense | 30.11 | 28.09 | 29.36 | 109.74 | 109.80 |
| (e) Finance Cost | 1.47 | 0.51 | 0.56 | 3.16 | 3.47 |
| (f) Depreciation, Depletion and Amortisation Expense | 1.30 | 4.44 | 6.05 | 14.61 | 17.75 |
| (g) Other Expense | 58.01 | 32.51 | 50.96 | 164.65 | 152.59 |
| Total Other Expenses | 58.01 | 32.51 | 50.96 | 164.65 | 152.59 |
| Total Expenses | 373.17 | 364.79 | 320.20 | 1320.88 | 1428.11 |
| 3 Total Profit before Exceptional Items and Tax | 54.99 | 19.22 | 21.70 | 105.37 | 71.34 |
| 4 Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 Total Profit before Tax | 54.99 | 19.22 | 21.70 | 105.37 | 71.34 |
| 6 Tax Expense | | | | | |
| 7 Current Tax | 10.50 | 5.50 | 5.10 | 23.00 | 17.50 |
| 8 Deferred Tax | (0.58) | 0.00 | (0.87) | (0.58) | (0.87) |
| 9 Total Tax Expenses | 9.92 | 5.50 | 4.23 | 22.42 | 16.63 |
| 10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 Net Profit Loss for the period from continuing operations | 45.07 | 13.72 | 17.47 | 82.95 | 54.71 |
| 12 Profit / (Loss) from discontinued operations before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 Tax Expenses of discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 14 Net Profit / (Loss) from discontinued operations after tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 16 | 45.07 | 13.72 | 17.47 | 82.95 | 54.71 |
| 17 Other Comprehensive Income net of Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 18 Total Comprehensive Income for the Period | 45.07 | 13.72 | 17.47 | 82.95 | 54.71 |



Jadhav Arun

| | | | | | | |
|-------|--|--------|--------|--------|--------|--------|
| 19 | Total profit or loss attributable to | | | | | |
| | Profit or loss, attributable to owners of parents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Total Profit or loss, attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 20 | Total comprehensive income for the period attributable to | | | | | |
| | Comprehensive Income for the period attributable to the owners of parents | | 0.00 | 0.00 | 0.00 | 0.00 |
| | Total comprehensive income for the period attributable to the owners of parent non-controlling interests | | 0.00 | 0.00 | 0.00 | 0.00 |
| 21 | Details of Equity Share Capital | | | | | |
| | Paid-Up Equity Share Capital | 299.03 | 299.03 | 299.03 | 299.03 | 299.03 |
| | Face Value of Equity Share Capital | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| 22 | Details of Debt Securities | | | | | |
| | Paid-Up Debt Capital | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Face Value of Debt Securities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 23 | Reserves Excluding Revaluation Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 24 | Debenture Redemption Reserve | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 25 | Earnings Per Share | | | | | |
| (i) | Earnings Per Share for continuing operations | | | | | |
| | Basic Earnings / (Loss) per share from continuing operations | 1.51 | 0.46 | 0.58 | 2.77 | 1.83 |
| | Diluted Earnings / (Loss) per share from continuing operations | 1.51 | 0.46 | 0.58 | 2.77 | 1.83 |
| (ii) | Earnings Per Share for discontinued operations | | | | | |
| | Basic Earnings / (Loss) per share from discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Diluted Earnings / (Loss) per share from discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (iii) | Earnings per Equity Share | | | | | |
| | Basic Earnings / (Loss) per share from continuing and discontinued operations | 1.51 | 0.46 | 0.58 | 2.77 | 1.83 |
| | Diluted Earnings / (Loss) per share from continuing and discontinued operations | 1.51 | 0.46 | 0.58 | 2.77 | 1.83 |
| 26 | Debt Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 27 | Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 28 | Interest Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

| | |
|--|-----------|
| NOTES | |
| 1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on June 30, 2021. | |
| 2. Results for the quarter and year ended 31st March, 2021, are in compliance with Indian Accounting Standards ('IndAS') notified by the Ministry of Corporate Affairs. | |
| 3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment. Hence no segment wise figures are published. | |
| 4. The figures for the quarter ended 31st March, 2021, are balancing figures between audited figures in respect of full financial year ended 31st March, 2021, and the published year to date figures upto the third quarter ended 31st December, 2020, which have been regrouped / rearranged wherever necessary. | |
| 5. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com. | |
| For, ISHITA DRUGS AND INDUSTRIES LIMITED | |
|   | |
| JAGDISH AGRAWAL | |
| MANAGING DIRECTOR | |
| Place | Ahmedabad |
| Date | 30-Jun-21 |
| DIN: 01031687 | |

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170
Website: www.ishitadrugs.com
Contact: +91 7226995613

Statement of Assets and Liabilities

Amount in Lakhs



| | Particulars | Year Ended | | Previous Year Ended | |
|---|--|-----------------|--|---------------------|--|
| | | 12 Months Ended | | 12 Months Ended | |
| | | Audited | | Audited | |
| | | 31-03-21 | | 31-03-20 | |
| | ASSETS | | | | |
| 1 | Non-current assets | | | | |
| | Property, plant and equipment | 99.58 | | 113.70 | |
| | Capital work-in-progress | | | | |
| | Investment property | | | | |
| | Goodwill | | | | |
| | Other intangible assets | | | | |
| | Intangible assets under development | | | | |
| | Biological assets other than bearer plants | | | | |
| | Investments accounted for using equity method | | | | |
| | Non-current financial assets | 99.58 | | 113.70 | |
| | Non-current investments | 22.59 | | 20.68 | |
| | Trade receivables, non-current | | | | |
| | Loans, non-current | | | | |
| | Other non-current financial assets | 5.07 | | 5.06 | |
| | Total Non-current financial assets | 27.66 | | 25.74 | |
| | Deferred tax assets (net) | | | | |
| | Other non-current assets | | | | |
| | Total Non-current Assets | 127.24 | | 139.44 | |
| 2 | Current assets | | | | |
| | Inventories | 65.44 | | 58.09 | |
| | Current financial assets | | | | |
| | Current investments | 288.50 | | 508.66 | |
| | Trade receivables, current | 152.38 | | 131.10 | |
| | Cash and cash equivalents | 175.32 | | 40.18 | |
| | Bank balance other than cash and cash equivalents | 78.51 | | 59.78 | |
| | Loans, current | 36.47 | | 14.44 | |
| | Other current financial assets | 2.63 | | 2.84 | |
| | Total current financial assets | 733.81 | | 757.00 | |
| | Current tax assets (net) | | | | |
| | Other current assets | | | | |
| | Total Current Assets | 0.00 | | 0.00 | |
| 3 | Non-current assets classified as held for sale | | | | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | | | | |
| | TOTAL ASSETS | 926.49 | | 954.54 | |



Jaydevi

| EQUITIES AND LIABILITIES | | | |
|--------------------------|---|---------------|---------------|
| 1 | Equity | | |
| | Equity attributable to owners of Parent | | |
| | Equity share capital | 299.03 | 299.03 |
| | Other equity | 480.04 | 397.08 |
| | Total Equity attributable to owners of Parent | 779.07 | 696.11 |
| | Non controlling interest | | |
| | Total Equity | 779.07 | 696.11 |
| 2 | Liabilities | | |
| | Non-current liabilities | | |
| | Non-current financial liabilities | | |
| | Borrowing, non-current | 0.00 | 4.19 |
| | Trade payables, non-current | | |
| | Other non-current financial liabilities | | |
| | Total Non-current financial liabilities | 0.00 | 4.19 |
| | Provisions, non-current | | |
| | Deferred tax liabilities (net) | 4.11 | 4.70 |
| | Deferred government grants, Non-current Other non-current liabilities | | |
| | Total Non-current liabilities | 4.11 | 4.70 |
| | Current liabilities | | |
| | Current financial liabilities | | |
| | Borrowing, current | 0.00 | 16.56 |
| | Trade payables, current | 98.24 | 189.36 |
| | Other current financial liabilities | 4.19 | 8.05 |
| | Total current financial liabilities | 102.44 | 213.97 |
| | Other current liabilities | 10.91 | 9.52 |
| | Provisions, current | 7.66 | 7.17 |
| | Current tax liabilities (Net) | 22.31 | 18.88 |
| | Deferred government grants, Current | | |
| | Total current liabilities | 40.88 | 35.57 |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | | |
| | Total Liabilities | 0.00 | 0.00 |
| | Total Equity and Liabilities | 926.49 | 954.54 |

For, ISHITA DRUGS AND INDUSTRIES LIMITED

JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 30-Jun-21

DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

AUDITED CASH FLOW STATEMENT

| Sr. No. | Particulars | Audited Year Ended 31.03.2021 Rs. In Lakhs | Audited Year Ended 31.03.2020 Rs. In Lakhs |
|---------|---|---|---|
| (A) | Cash flow from operating activities : | | |
| | Profit before tax | 105.37 | 71.34 |
| | Add : Depreciation | 14.61 | 17.75 |
| | Interest & Other financial charges | 3.16 | 3.47 |
| | Less : Interest received | 4.03 | 4.56 |
| | Dividend received | 0.01 | 0.01 |
| | Income from Investments | 27.31 | 11.67 |
| | Operating profit before change in working capital | 91.79 | 76.33 |
| | Add : Trade Debtors | (21.28) | (13.06) |
| | Decrease/(Increase) in Inventory | (7.35) | 15.78 |
| | Decrease/(Increase) in Loans and advances | (21.83) | (1.05) |
| | Less : Provision for Taxation | 23.00 | 17.50 |
| | Decrease/(Increase) Shore Term Provision | (1.88) | 0.46 |
| | Decrease/(Increase) Trade Creditors, Current liabilities & Provisions | 87.69 | (44.72) |
| | Net cash generated from operating activities (A) | (67.48) | 104.75 |
| (B) | Cash inflow from investing activities : | | |
| | Add : Investment sold / (purchased) | 218.26 | (125.55) |
| | Dividend received | 0.01 | 0.01 |
| | Income from Investments | 27.31 | 11.67 |
| | Less : Investment in fixed assets | 0.49 | 1.46 |
| | Net cash generated from investing activities (B) | 245.09 | (115.33) |
| (C) | Cash flow from financial activities : | | |
| | Add : Interest received | 4.03 | 4.56 |
| | Borrowings | (24.61) | 8.34 |
| | Less : Interest & Other financial charges | 3.16 | 3.47 |
| | Net cash generated from financial activities (C) | (23.74) | 9.42 |
| | Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C) | 153.87 | (1.15) |
| | Opening balance of Cash and cash equivalents | 99.96 | 101.11 |
| | Closing balance of Cash and cash equivalents | 253.83 | 99.96 |
| | Net Increase/(decrease) in Cash & Cash Equivalents | 153.87 | (1.15) |

Note : Figures in bracket indicate negative value

Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place Ahmedabad

Date 30-Jun-21



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Date: 30.06.2021

To,
The Department of Corporate Services,
The BSE Limited
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Security Code: 524400

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015 w.r.t. Audit Report with unmodified opinion

Pursuant to Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, have issued an Audit report with unmodified opinion on Standalone Annual Financial Results of the Company for the year ended on 31st March, 2021.

Kindly take the above on your records.

Thanking You

For Ishita Drugs and Industries Limited





Authorized Signatory

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359